Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Ocrelizumab in Moderate to Severe Rheumatoid Arthritis
NCT00077870Phase 2Completed
- Sponsor
- Genentech
- Start
- Feb 2004
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial of ocrelizumab in rheumatoid arthritis (RA) (6 arms), sponsored by Genentech. Primary endpoint: Safety and tolerability of ocrelizumab. Started Feb 2004; status: completed.
02
Drugs
ocrelizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00077870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00077870.